EUVIMEDDescoperă EUVIMED
Open access

A simple MRI / PET ‐derived index predicts relapse‐free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Ikuma Shioi iD, Takuya Shiraishi iD, Kosei Uehara iD, Yutaro Shimizu, Nobuhiro Hosoi, Gendensuren Dorjkhorloo, Chika Katayama, Yuta Shibasaki, Chika Komine, Takuhisa Okada, Akiharu Kimura iD, Akihiko Sano iD and 4 more

Colorectal Disease · 2026-08 · 28 (8)

DOI: 10.1111/codi.70560 ↗

At a glance

Journal article in Colorectal Disease, published online on 2026-07-23. Written by Ikuma Shioi and 15 co-authors. Institution: Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. Major MEDLINE topics: Rectal Neoplasms, Neoadjuvant Therapy, Magnetic Resonance Imaging, Positron Emission Tomography Computed Tomography. 26 references. The full text is freely available in PubMed Central. Funded by: Japan Society for the Promotion of Science.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Aim

Reliable pretreatment biomarkers for predicting resistance to standard chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) remain lacking. This study evaluated the prognostic value of the tumour area (TA)‐to‐maximum standardized uptake value (SUVmax) [T/S] ratio, a novel imaging index derived from magnetic resonance imaging (MRI) and 18 F‐fluorodeoxyglucose positron emission tomography‐computed tomography (PET‐CT), for predicting oncological outcomes in LARC.

Method

We retrospectively analysed 68 patients with LARC who underwent preoperative CRT followed by curative resection between 2013 and 2024. TA was measured on axial T2‐weighted MRI, and SUVmax was obtained from PET‐CT. The T/S ratio was calculated as TA/SUVmax. Receiver operating characteristic analysis determined the optimal cut‐off for relapse‐free survival (RFS). Cox proportional hazards models identified independent prognostic factors. Immunohistochemical analysis of L‐type amino acid transporter 1 (LAT1) was performed in 33 patients without CRT to explore biological relevance.

Results

The T/S ratio showed superior predictive accuracy for RFS (area under the curve, 0.714) than for TA (0.616) and SUVmax (0.574). Patients with a high T/S ratio (cut‐off 55.81) demonstrated significantly poorer 3‐year RFS (51.8% vs. 84.0%, p = 0.002). Multivariate analysis confirmed high T/S ratio as an independent RFS predictor ( HR 4.59; 95% CI: 1.27–16.55; p = 0.019). Tumours with high T/S ratios tended to exhibit elevated LAT1 expression, potentially reflecting a CRT ‐resistant phenotype.

Conclusions

The pretreatment T/S ratio is a simple, noninvasive biomarker that independently predicts RFS in patients with LARC undergoing CRT. This index may assist in risk stratification and individualized neoadjuvant strategy selection.

Subjects

MeSH terms (MEDLINE)

Rectal NeoplasmsNeoadjuvant TherapyMagnetic Resonance ImagingPositron Emission Tomography Computed TomographyChemoradiotherapyHumansRetrospective StudiesFemaleMaleDisease-Free SurvivalPrognosisMiddle AgedAgedFluorodeoxyglucose F18Predictive Value of TestsRadiopharmaceuticalsNeoplasm Recurrence, LocalChemoradiotherapy, AdjuvantROC CurveAdult

Author keywords

18F‐FDG PET‐CTchemoradiotherapylocally advanced rectal cancermagnetic resonance imagingrelapse‐free survival

Substances

Fluorodeoxyglucose F18Radiopharmaceuticals

Authors and institutions

  • Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
  • Division of Integrated Oncology Research, Gunma University, Initiative for Advanced Research (GIAR), Maebashi, Gunma, Japan.

ORCID profiles: Ikuma Shioi, Takuya Shiraishi, Kosei Uehara, Akiharu Kimura, Akihiko Sano, Makoto Sakai, Ken Shirabe

Funding

  • Japan Society for the Promotion of Science

Cite

APA

Shioi, I., Shiraishi, T., Uehara, K., Shimizu, Y., Hosoi, N., Dorjkhorloo, G., Katayama, C., Shibasaki, Y., Komine, C., Okada, T., Kimura, A., Sano, A., Yokobori, T., Sakai, M., Shirabe, K., & Saeki, H. (2026). A simple MRI / PET ‐derived index predicts relapse‐free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Colorectal Disease, 28(8). https://doi.org/10.1111/codi.70560

Vancouver

Shioi I, Shiraishi T, Uehara K, Shimizu Y, Hosoi N, Dorjkhorloo G, et al. A simple MRI / PET ‐derived index predicts relapse‐free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Colorectal Disease. 2026;28(8). doi:10.1111/codi.70560

BibTeX
@article{Shioi2026,
  author = {Shioi, Ikuma and Shiraishi, Takuya and Uehara, Kosei and Shimizu, Yutaro and Hosoi, Nobuhiro and Dorjkhorloo, Gendensuren and Katayama, Chika and Shibasaki, Yuta and Komine, Chika and Okada, Takuhisa and Kimura, Akiharu and Sano, Akihiko and Yokobori, Takehiko and Sakai, Makoto and Shirabe, Ken and Saeki, Hiroshi},
  title = {A simple MRI / PET ‐derived index predicts relapse‐free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer},
  journal = {Colorectal Disease},
  year = {2026},
  volume = {28},
  number = {8},
  doi = {10.1111/codi.70560}
}
Start for free →